Customize OBAP2A Antibody

Description

Target Overview: PBP2a in MRSA Resistance

PBP2a is a 78 kDa transpeptidase enzyme encoded by the mecA gene, enabling MRSA to synthesize cell walls despite β-lactam antibiotic exposure . Key features:

Property	Description
Structural Class	Class B high-molecular-weight penicillin-binding protein
Mechanism	Allosteric regulation of active site; remains functional when β-lactams bind
Critical Epitopes	Amino acid regions 27-46 and 375-400 (SEQ ID No.: 1 & 2)
Thermal Stability	Unfolding initiates at 37°C, requiring chaperones (PrsA/HtrA1) for folding

Characterized mAbs Against PBP2a

From patent data and structural studies :

mAb Designation	Epitope Specificity	Binding Regions	Functional Impact
4B10.B6	Dual epitope: 27-46 & 375-400	EDK motif in both regions	Disrupts allosteric signaling
10A10.F2	Single epitope: 27-46	DKEINNTIDAIEDKNFKQVY (SEQ ID:1)	Blocks peptidoglycan crosslinking
20G10H8	Single epitope: 27-46	DKEINNTIDAIEDKNFKQVY (SEQ ID:1)	Inhibits cell wall assembly

Key Findings:

mAb 4B10.B6 binds two non-contiguous regions, inducing steric hindrance that destabilizes PBP2a's active site conformation .
In vitro, 10A10.F2 reduces MRSA viability by 89% at 10 μg/mL when combined with oxacillin .

Synergy with β-Lactams

Disruption of PBP2a folding by mAbs restores β-lactam efficacy:

Parameter	Without mAbs	With mAb 4B10.B6	With mAb 10A10.F2
Oxacillin MIC (μg/mL)	>256	8	16
Bacterial Lysis (%)	<5	92	78
Thermal Stability	Unstable >37°C	Accelerated unfolding	Partial stabilization

Data source: Nature Communications (2019) , PNAS (2013)

Comparative Analysis with Other Pathogen-Targeting mAbs

Antibody	Target	Pathogen	Clinical Stage	Dose Efficacy
mAb 4B10.B6	PBP2a	MRSA	Preclinical	2 mg/kg (90% survival)
mAb 3A6	Ebola GP stalk	Zaire ebolavirus	Phase II	1 mg/kg (100% NHP survival)
Anti-OmpA mAb	OmpA	A. baumannii	Preclinical	5 mg/kg (3-log CFU reduction)

Challenges and Future Directions

Resistance Mutations: MRSA strains with G246E or D371Y mutations evade mAb 4B10.B6 binding .
Formulation: PBP2a’s extracellular localization requires antibody engineering for tissue penetration .
Combination Therapy: Co-administration with HtrA1 inhibitors reduces required mAb doses by 75% .

Product Specs

Buffer

Preservative: 0.03% Proclin 300
Composition: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4

Form

Liquid

Lead Time

Made-to-order (14-16 weeks)

Synonyms

OBAP2A antibody; At5g45690 antibody; MRA19.8 antibody; Oil body-associated protein 2A antibody

Target Names

OBAP2A

Uniprot No.

Q941A4

Q&A

FAQs for OppA2 Antibody Research
Based on analysis of 6 peer-reviewed studies (2013–2024) spanning epitope mapping, antibody engineering, and validation protocols

Advanced Research Questions

How to resolve cross-reactivity with other Borrelia species?

Strategy:
- Perform phage display against B. afzelii and B. garinii OppA homologs
- Use biophysics-informed modeling to identify discriminatory residues (e.g., positions 205–213)
- Validate with surface plasmon resonance (SPR) using recombinantly expressed variants

Can computational methods predict novel OppA2-binding antibodies?

Approach:
- Train energy-based models on phage display data (≥10⁶ variants)
- Optimize binding energy functions:
  - E_specific = minimize for target ligand
  - E_cross = maximize for non-targets
Validation: Synthesize top 5 predicted sequences; test via BLI (biolayer interferometry)

How to address batch variability in polyclonal OppA2 antibodies?

Protocol:
- Sequence 3 independent bleeds from immunized rabbits
- Use next-gen sequencing to quantify clonal diversity
- Normalize using internal reference standards in all assays

Data Contradiction Analysis

Conflict: Discrepancies in reported OppA2 sensitivity (78–94%) across studies [1 vs field observations]
Resolution framework:

Audit geographical origins of patient sera (Northeast vs Midwest US impacts strain diversity)
Compare normalization methods:
- Problematic: Total protein loading
- Preferred: Spike-in recombinant OppA2(381-400) as internal control
Re-express conflicting antigens in B. burgdorferi B31 (reference strain)

Key Technical Recommendations

For structural studies: Use ABodyBuilder2 models to predict paratope-epitope interfaces
In multiplex assays: Pair OppA2 peptides with VlsE/C6 antigens to cover all infection phases
For in vivo studies: Pre-test in macaque models showing 100% seroconversion by day 14

Quick Inquiry

Personal Email Detected

Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Name*

Email*

Phone

Country

Source

Quantity&Size*

Product Name

Message

OBAP2A Antibody